Ferdinando E. Vegni M.D. Msc

Ferdinando E. Vegni MD PhD MSc is a highly experienced leader in patient safety and risk management, currently serving as Senior Vice President and Head of Global Patient Safety & Risk Management at Alnylam Pharmaceuticals since September 2024. Prior to this role, Ferdinando held various positions at Bristol Myers Squibb from November 2019 to September 2024, including Global Head of Patient Safety in Haematology and Cell Therapy, where leadership was provided to ensure benefit-risk evaluations from early clinical development through product lifecycle management. Ferdinando's previous experience includes key roles at Celgene and Pfizer, contributing to drug safety and risk management strategies across oncology and hematology, as well as corporate strategy and medical oversight in large-scale clinical development. Ferdinando holds multiple advanced degrees, including a PhD in Pharmacoepidemiology from the London School of Hygiene and Tropical Medicine.